Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1529828

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1529828

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Biologics Regulatory Affairs Outsourcing Market Growth & Trends:

The global biologics regulatory affairs outsourcing market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 8.87% from 2024 to 2030, according to a new report by Grand View Research, Inc. Globalization of biopharmaceutical companies is one of the major growth drivers boosting overall market demand. Emerging markets of Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical companies, thereby stimulating the demand for regulatory services. Furthermore, the presence of EMA- and/or FDA-approved facilities in emerging economies is anticipated to increase foreign investments in the country and the demand for regulatory services, such as legal representation and regulatory consulting services.

A significant increase has been witnessed in the number of clinical trials conducted in emerging economies. This can be attributed to the availability of skilled labor, advanced technologies, and infrastructure facilities at relatively lower costs than developed economies such as the U.S., which is expected to stimulate the demand for regulatory services such as clinical trial applications & product registrations in these regions. Emerging economies contribute to more than 30.0% of total clinical trial applications submitted across the globe, and the share is expected to increase over the coming years, contributing to market growth.

Several biopharmaceutical companies are focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies face several challenges with regard to complying with global regulations, which can be a lengthy and tedious process. Thus, the race to launch a novel molecule in the market in a feasible timeline and at a reasonable cost will likely propel the demand for service providers. Furthermore, many small- and medium-scale biopharma companies lacking in-house capabilities are inclined towards outsourcing regulatory affairs, which is estimated to positively influence the industry's progression.

Growth in markets for biosimilars, orphan drugs, personalized medicines, adaptive trial designs, and others is projected to boost the demand for regulatory specialization in these areas. As several companies expand into new avenues, the increasing need for skilled service providers with experience in regulations leads to the necessity to comply with regulations. Government support, especially in developed economies, has significantly increased the development of orphan drugs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services in this segment.

Biologics Regulatory Affairs Outsourcing Market Report Highlights:

  • The regulatory writing & publishing segment held the largest market share in 2023. The high segment growth is owing to the increasing complexity of biologics requiring precise and comprehensive documentation, stringent global regulatory requirements demanding thorough submissions, and the need for specialized expertise to ensure compliance. The rapid pace of innovation in biologics, such as gene therapies and biosimilars, necessitates up-to-date knowledge of evolving regulations is anticipated overall market growth
  • The pharmaceutical companies segment accounted for the largest revenue share of over 76.23% in 2023. The segmental growth is owing to a high number of clinical trials for biologics, a growing product pipeline for ATMPs, stringent regulatory guidelines for advanced therapeutics, and growing outsourcing trends for non-core activities such as clinical trials, data management, regulatory compliance etc., are few factors further boosting segment growth
  • The monoclonal antibodies (mAbs) segment accounted for the largest revenue share in 2023. The segmental growth is owing to rapid advancements in mAb technology, including novel delivery methods and therapeutic targets, which require updated and precise regulatory strategies leading to overall market growth potential
  • North America dominated the market with a share of 30.54% in 2023. The regional market growth is owing to high R&D activities and government initiatives for clinical trials. Moreover, the strong presence of biopharmaceutical companies and outsourcing service providers is another major factor expected to propel market growth. For instance, in October 2021, the U.S. FDA approved 11 novel clinical trial research, resulting in over USD 25 million in funding over the next four years to support the development of innovative drugs to treat rare diseases
Show more
Product Code: GVR-4-68040-369-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1:
    • 1.10.2. Objective - 2:
    • 1.10.3. Objective - 3:
    • 1.10.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service Outlook
    • 2.2.2. Phase Outlook
    • 2.2.3. Modality Outlook
    • 2.2.4. Phase by Service Outlook
    • 2.2.5. Phase by Modality Outlook
    • 2.2.6. Modality by Service Outlook
    • 2.2.7. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Biologics Regulatory Affairs Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Number of Clinical Trials
      • 3.2.1.2. Increasing Adoption of the Personalized Medicine and Novel Therapeutics
      • 3.2.1.3. Rising R&D Investment in the Healthcare Industry
      • 3.2.1.4. Advancements in the Regulatory Affairs Market
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Managing Relationships
  • 3.3. Technological Advancements
    • 3.3.1. Existing and Emerging Use of Technology and Preferred Tools
    • 3.3.2. Differentiating In-House Tools Vs Widely Available
    • 3.3.3. Key Technology Pillars
      • 3.3.3.1. Digital Transformation and Data Integrity
      • 3.3.3.2. Artificial Intelligence, Machine Learning/Automation
      • 3.3.3.3. Data Analysis and Predictive Modeling
      • 3.3.3.4. Automation of Routine Tasks
      • 3.3.3.5. Compliance Monitoring
      • 3.3.3.6. Discovery and Development
      • 3.3.3.7. Regulatory Guidelines Related to AI/ML
    • 3.3.4. Big Data and Analytics
    • 3.3.5. RTP, Text Processing and Analytics
    • 3.3.6. Speech and Video Analytics
    • 3.3.7. IoT (Internet Of Things)
    • 3.3.8. AI Tools
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Biologics Regulatory Affairs Outsourcing Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Biologics Regulatory Affairs Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 4.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
    • 4.3.1. Regulatory Consulting
      • 4.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.2. Strategy & Development Planning
      • 4.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.3. QA Consulting
      • 4.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.4. Agent Services
      • 4.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.5. Others
      • 4.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.2. Legal Representation
      • 4.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.3. Regulatory Writing & Publishing
      • 4.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.4. Product Registration & Clinical Trial Applications
      • 4.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.5. Regulatory Submissions
      • 4.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.6. Regulatory Operations
      • 4.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.7. Other Services
      • 4.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biologics Regulatory Affairs Outsourcing Market: Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 5.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
    • 5.3.1. Preclinical
      • 5.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 5.3.2. Clinical
      • 5.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.2. Phase I
      • 5.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.3. Phase II
      • 5.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.4. Phase III
      • 5.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.5. Phase IV
      • 5.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biologics Regulatory Affairs Outsourcing Market: Modality Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 6.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
  • 6.4. Monoclonal Antibodies (mAbs)
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Recombinant Proteins
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Vaccines
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.7. Cell & Gene Therapies
    • 6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.8. Biosimilars
    • 6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biologics Regulatory Affairs Outsourcing Market: Phase by Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 7.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Service, 2018 to 2030 (USD Million)
    • 7.3.1. Preclinical
      • 7.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.2. Regulatory Consulting
      • 7.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.3. Legal Representation
      • 7.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.4. Regulatory Writing & Publishing
      • 7.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.5. Product Registration & Clinical Trial Applications
      • 7.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.6. Regulatory Submissions
      • 7.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.7. Regulatory Operations
      • 7.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.8. Other Services
      • 7.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.3.2. Clinical
      • 7.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.2. Regulatory Consulting
      • 7.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.3. Legal Representation
      • 7.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.4. Regulatory Writing & Publishing
      • 7.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.5. Product Registration & Clinical Trial Applications
      • 7.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.6. Regulatory Submissions
      • 7.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.7. Regulatory Operations
      • 7.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.8. Other Services
      • 7.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Biologics Regulatory Affairs Outsourcing Market: Phase by Modality Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 8.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Modality, 2018 to 2030 (USD Million)
    • 8.3.1. Preclinical
      • 8.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.2. Monoclonal Antibodies (mAbs)
      • 8.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.3. Recombinant Proteins
      • 8.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.4. Vaccines
      • 8.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.5. Cell & Gene Therapies
      • 8.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.6. Biosimilars
      • 8.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.7. Others
      • 8.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.3.2. Clinical
      • 8.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.2. Monoclonal Antibodies (mAbs)
      • 8.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.3. Recombinant Proteins
      • 8.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.4. Vaccines
      • 8.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.5. Cell & Gene Therapies
      • 8.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.6. Biosimilars
      • 8.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.7. Others
      • 8.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Biologics Regulatory Affairs Outsourcing Market: Modality by Service Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 9.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Modality by Service, 2018 to 2030 (USD Million)
    • 9.3.1. Monoclonal Antibodies (mAbs)
      • 9.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.2. Regulatory Consulting
      • 9.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.3. Legal Representation
      • 9.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.4. Regulatory Writing & Publishing
      • 9.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.5. Product Registration & Clinical Trial Applications
      • 9.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.6. Regulatory Submissions
      • 9.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.7. Regulatory Operations
      • 9.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.8. Other Services
      • 9.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.2. Recombinant Proteins
      • 9.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.2. Regulatory Consulting
      • 9.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.3. Legal Representation
      • 9.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.4. Regulatory Writing & Publishing
      • 9.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.5. Product Registration & Clinical Trial Applications
      • 9.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.6. Regulatory Submissions
      • 9.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.7. Regulatory Operations
      • 9.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.8. Other Services
      • 9.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.3. Vaccines
      • 9.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.2. Regulatory Consulting
      • 9.3.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.3. Legal Representation
      • 9.3.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.4. Regulatory Writing & Publishing
      • 9.3.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.5. Product Registration & Clinical Trial Applications
      • 9.3.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.6. Regulatory Submissions
      • 9.3.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.7. Regulatory Operations
      • 9.3.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.8. Other Services
      • 9.3.3.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.4. Cell & Gene Therapies
      • 9.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.2. Regulatory Consulting
      • 9.3.4.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.3. Legal Representation
      • 9.3.4.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.4. Regulatory Writing & Publishing
      • 9.3.4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.5. Product Registration & Clinical Trial Applications
      • 9.3.4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.6. Regulatory Submissions
      • 9.3.4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.7. Regulatory Operations
      • 9.3.4.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.8. Other Services
      • 9.3.4.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.5. Biosimilars
      • 9.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.2. Regulatory Consulting
      • 9.3.5.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.3. Legal Representation
      • 9.3.5.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.4. Regulatory Writing & Publishing
      • 9.3.5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.5. Product Registration & Clinical Trial Applications
      • 9.3.5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.6. Regulatory Submissions
      • 9.3.5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.7. Regulatory Operations
      • 9.3.5.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.8. Other Services
      • 9.3.5.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.6. Others
      • 9.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.2. Regulatory Consulting
      • 9.3.6.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.3. Legal Representation
      • 9.3.6.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.4. Regulatory Writing & Publishing
      • 9.3.6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.5. Product Registration & Clinical Trial Applications
      • 9.3.6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.6. Regulatory Submissions
      • 9.3.6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.7. Regulatory Operations
      • 9.3.6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.8. Other Services
      • 9.3.6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 10. Biologics Regulatory Affairs Outsourcing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Competitive Market share, by Industry (2023)
  • 11.3. Competition Mapping by Service Type (2023)
  • 11.4. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.5. Company Profiles
    • 11.5.1. Lonza AG
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Service Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. Wuxi Apptec Inc.
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Service Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. Thermo Fisher Scientific Inc.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Service Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. Eurofins Scientific SE
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Service Benchmarking
      • 11.5.4.4. Strategic Initiatives
    • 11.5.5. Freyrsolutions
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Service Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. Catalent Inc.
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Service Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. Piramal Group
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Service Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. AGC Biologics
      • 11.5.8.1. Company Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Service Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. ICON Plc.
      • 11.5.9.1. Company Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Service Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. Charles River Laboratories International, Inc.
      • 11.5.10.1. Company Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Service Benchmarking
      • 11.5.10.4. Strategic Initiatives
    • 11.5.11. Labcorp
      • 11.5.11.1. Company Overview
      • 11.5.11.2. Financial Performance
      • 11.5.11.3. Service Benchmarking
      • 11.5.11.4. Strategic Initiatives
    • 11.5.12. Parexel International
      • 11.5.12.1. Company Overview
      • 11.5.12.2. Financial Performance
      • 11.5.12.3. Service Benchmarking
      • 11.5.12.4. Strategic Initiatives
    • 11.5.13. Medpace Holdings, Inc.
      • 11.5.13.1. Company Overview
      • 11.5.13.2. Financial Performance
      • 11.5.13.3. Service Benchmarking
      • 11.5.13.4. Strategic Initiatives
    • 11.5.14. IQVIA
      • 11.5.14.1. Company Overview
      • 11.5.14.2. Financial Performance
      • 11.5.14.3. Service Benchmarking
      • 11.5.14.4. Strategic Initiatives
    • 11.5.15. Syneos Health
      • 11.5.15.1. Company Overview
      • 11.5.15.2. Financial Performance
      • 11.5.15.3. Service Benchmarking
      • 11.5.15.4. Strategic Initiatives
    • 11.5.16. SGS SA (SGS)
      • 11.5.16.1. Company Overview
      • 11.5.16.2. Financial Performance
      • 11.5.16.3. Service Benchmarking
      • 11.5.16.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-369-4

List of Tables

  • 1. List of Secondary Sources
  • 2. List of Abbreviations
  • 3. Global Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 4. Global Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 5. Global Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 6. Global Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 7. Global Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 8. Global Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 9. Global Biologics Regulatory Affairs Outsourcing, by Region, 2018 - 2030 (USD Million)
  • 10. North America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 11. North America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 12. North America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 13. North America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 14. North America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 15. North America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 16. North America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 17. U.S. Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 18. U.S. Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 19. U.S. Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 20. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 21. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 22. U.S. Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 23. Canada Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 24. Canada Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 25. Canada Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 26. Canada Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 27. Canada Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 28. Canada Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 29. Mexico Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 30. Mexico Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 31. Mexico Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 32. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 33. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 34. Mexico Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 35. Europe Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 36. Europe Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 37. Europe Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 38. Europe Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 39. Europe Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 40. Europe Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 41. Europe Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 42. Germany Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 43. Germany Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 44. Germany Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 45. Germany Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 46. Germany Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 47. Germany Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 48. UK Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 49. UK Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 50. UK Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 51. UK Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 52. UK Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 53. UK Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 54. France Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 55. France Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 56. France Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 57. France Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 58. France Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 59. France Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 60. Italy Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 61. Italy Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 62. Italy Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 63. Italy Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 64. Italy Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 65. Italy Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 66. Spain Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 67. Spain Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 68. Spain Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 69. Spain Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 70. Spain Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 71. Spain Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 72. Denmark Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 73. Denmark Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 74. Denmark Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 75. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 76. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 77. Denmark Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 78. Sweden Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 79. Sweden Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 80. Sweden Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 81. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 82. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 83. Sweden Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 84. Norway Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 85. Norway Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 86. Norway Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 87. Norway Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 88. Norway Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 89. Norway Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 90. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 91. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 92. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 93. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 94. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 95. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 96. Asia Pacific Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 97. China Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 98. China Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 99. China Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 100. China Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 101. China Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 102. China Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 103. Japan Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 104. Japan Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 105. Japan Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 106. Japan Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 107. Japan Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 108. Japan Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 109. India Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 110. India Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 111. India Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 112. India Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 113. India Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 114. India Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 115. South Korea Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 116. South Korea Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 117. South Korea Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 118. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 119. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 120. South Korea Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 121. Australia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 122. Australia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 123. Australia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 124. Australia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 125. Australia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 126. Australia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 127. Thailand Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 128. Thailand Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 129. Thailand Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 130. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 131. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 132. Thailand Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 133. Latin America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 134. Latin America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 135. Latin America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 136. Latin America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 137. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 138. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 139. Latin America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 140. Brazil Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 141. Brazil Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 142. Brazil Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 143. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 144. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 145. Brazil Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 146. Argentina Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 147. Argentina Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 148. Argentina Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 149. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 150. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 151. Argentina Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 152. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 153. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 154. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 155. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 156. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 157. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 158. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 159. South Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 160. South Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 161. South Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 162. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 163. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 164. South Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 165. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 166. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 167. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 168. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 169. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 170. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 171. UAE Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 172. UAE Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 173. UAE Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 174. UAE Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 175. UAE Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 176. UAE Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 177. Kuwait Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 178. Kuwait Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 179. Kuwait Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 180. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 181. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 182. Kuwait Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

List of Figures

  • 1. Information Procurement
  • 2. Primary Research Pattern
  • 3. Market Research Approaches
  • 4. Value Chain-Based Sizing & Forecasting
  • 5. Market Formulation & Validation
  • 6. Biologics Regulatory Affairs Outsourcing, Market Segmentation
  • 7. Market Driver Relevance Analysis (Current & Future Impact)
  • 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • 9. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 10. Porter's Five Forces Analysis
  • 11. Regional Marketplace: Key Takeaways
  • 12. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • 13. Global Biologics Regulatory Affairs Outsourcing, for Strategy & Development Planning, 2018 - 2030 (USD Million)
  • 14. Global Biologics Regulatory Affairs Outsourcing, for QA Consulting, 2018 - 2030 (USD Million)
  • 15. Global Biologics Regulatory Affairs Outsourcing, for Agent Services, 2018 - 2030 (USD Million)
  • 16. Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • 17. Global Biologics Regulatory Affairs Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • 18. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 19. Global Biologics Regulatory Affairs Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 20. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • 21. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • 22. Global Biologics Regulatory Affairs Outsourcing, for Preclinical, 2018 - 2030 (USD Million)
  • 23. Global Biologics Regulatory Affairs Outsourcing, for Clinical, 2018 - 2030 (USD Million)
  • 24. Global Biologics Regulatory Affairs Outsourcing, for Phase I, 2018 - 2030 (USD Million)
  • 25. Global Biologics Regulatory Affairs Outsourcing, for Phase II, 2018 - 2030 (USD Million)
  • 26. Global Biologics Regulatory Affairs Outsourcing, for Phase III, 2018 - 2030 (USD Million)
  • 27. Global Biologics Regulatory Affairs Outsourcing, for Phase IV, 2018 - 2030 (USD Million)
  • 28. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • 29. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Legal Representation, 2018 - 2030 (USD Million)
  • 30. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 31. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 32. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • 33. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Operations, 2018 - 2030 (USD Million)
  • 34. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Other Services, 2018 - 2030 (USD Million)
  • 35. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • 36. Global Biologics Regulatory Affairs Outsourcing, for Clinical Legal Representation, 2018 - 2030 (USD Million)
  • 37. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 38. Global Biologics Regulatory Affairs Outsourcing, for Clinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 39. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • 40. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Operations, 2018 - 2030 (USD Million)
  • 41. Global Biologics Regulatory Affairs Outsourcing, for Clinical Other Services, 2018 - 2030 (USD Million)
  • 42. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 43. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • 44. Global Biologics Regulatory Affairs Outsourcing, for Vaccines, 2018 - 2030 (USD Million)
  • 45. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 46. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars, 2018 - 2030 (USD Million)
  • 47. Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • 48. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 49. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • 50. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Vaccines, 2018 - 2030 (USD Million)
  • 51. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 52. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
  • 53. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Others, 2018 - 2030 (USD Million)
  • 54. Global Biologics Regulatory Affairs Outsourcing, for Clinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 55. Global Biologics Regulatory Affairs Outsourcing, for Clinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • 56. Global Biologics Regulatory Affairs Outsourcing, for Clinical Vaccines, 2018 - 2030 (USD Million)
  • 57. Global Biologics Regulatory Affairs Outsourcing, for Clinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 58. Global Biologics Regulatory Affairs Outsourcing, for Clinical Biosimilars, 2018 - 2030 (USD Million)
  • 59. Global Biologics Regulatory Affairs Outsourcing, for Clinical Others, 2018 - 2030 (USD Million)
  • 60. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Consulting, 2018 - 2030 (USD Million)
  • 61. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Legal Representation, 2018 - 2030 (USD Million)
  • 62. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 63. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 64. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Submissions, 2018 - 2030 (USD Million)
  • 65. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Operations, 2018 - 2030 (USD Million)
  • 66. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Other Services, 2018 - 2030 (USD Million)
  • 67. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Consulting, 2018 - 2030 (USD Million)
  • 68. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Legal Representation, 2018 - 2030 (USD Million)
  • 69. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 70. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 71. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Submissions, 2018 - 2030 (USD Million)
  • 72. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Operations, 2018 - 2030 (USD Million)
  • 73. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Other Services, 2018 - 2030 (USD Million)
  • 74. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Consulting, 2018 - 2030 (USD Million)
  • 75. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Legal Representation, 2018 - 2030 (USD Million)
  • 76. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 77. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 78. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Submissions, 2018 - 2030 (USD Million)
  • 79. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Operations, 2018 - 2030 (USD Million)
  • 80. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Other Services, 2018 - 2030 (USD Million)
  • 81. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Consulting, 2018 - 2030 (USD Million)
  • 82. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Legal Representation, 2018 - 2030 (USD Million)
  • 83. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 84. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 85. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Submissions, 2018 - 2030 (USD Million)
  • 86. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Operations, 2018 - 2030 (USD Million)
  • 87. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Other Services, 2018 - 2030 (USD Million)
  • 88. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Consulting, 2018 - 2030 (USD Million)
  • 89. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Legal Representation, 2018 - 2030 (USD Million)
  • 90. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 91. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 92. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Submissions, 2018 - 2030 (USD Million)
  • 93. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Operations, 2018 - 2030 (USD Million)
  • 94. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Other Services, 2018 - 2030 (USD Million)
  • 95. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Consulting, 2018 - 2030 (USD Million)
  • 96. Global Biologics Regulatory Affairs Outsourcing, for Others Legal Representation, 2018 - 2030 (USD Million)
  • 97. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 98. Global Biologics Regulatory Affairs Outsourcing, for Others Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 99. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Submissions, 2018 - 2030 (USD Million)
  • 100. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Operations, 2018 - 2030 (USD Million)
  • 101. Global Biologics Regulatory Affairs Outsourcing, for Others Other Services, 2018 - 2030 (USD Million)
  • 102. Regional Outlook, 2023 & 2030
  • 103. North America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 104. U.S. Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 105. Canada Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 106. Mexico Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 107. Europe Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 108. Germany Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 109. UK Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 110. France Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 111. Italy Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 112. Spain Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 113. Denmark Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 114. Sweden Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 115. Norway Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 116. Asia Pacific Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 117. Japan Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 118. China Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 119. India Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 120. Australia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 121. South Korea Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 122. Thailand Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 123. Latin America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 124. Brazil Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 125. Argentina Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 126. Middle East and Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 127. South Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 128. Saudi Arabia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 129. UAE Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 130. Kuwait Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!